Unknown

Dataset Information

0

Discovery of a highly selective JAK3 inhibitor for the treatment of rheumatoid arthritis.


ABSTRACT: Janus tyrosine kinase 3 (JAK3) is expressed in lymphoid cells and is involved in the signalling of T cell functions. The development of a selective JAK3 inhibitor has been shown to have a potential benefit in the treatment of autoimmune disorders. In this article, we developed the 4-aminopiperidine-based compound RB1, which was highly selective for JAK3 inhibition, with an IC50 of value of 40?nM, but did not inhibit JAK1, JAK2 or tyrosine kinase 2 (TYK2) at concentrations up to 5?µM. Furthermore, RB1 also exhibited favourable selectivity against a panel of representative kinases. In a battery of cytokine-stimulated cell-based assays, this potent inhibitor of JAK3 activity with good selectivity against other kinases could potently inhibit JAK3 activity over the activity of JAK1 or JAK2 (over at least 100-fold). A combination of liquid chromatography-mass spectrometry (LC-MS) experiments validated that RB1 covalently modified the unique cysteine 909 residue in JAK3. In vivo, RB1 exerted significantly improved pathology in the joints of a collagen-induced arthritis mouse model. The reasonable pharmacokinetics properties (F?=?72.52%, T1/2?=?14.6?h) and favourable results of toxicology experiments (LD50?>?2?g/kg) suggest that RB1 has the potential to be an efficacious treatment for RA.

SUBMITTER: Pei H 

PROVIDER: S-EPMC5869712 | biostudies-literature | 2018 Mar

REPOSITORIES: biostudies-literature

altmetric image

Publications

Discovery of a highly selective JAK3 inhibitor for the treatment of rheumatoid arthritis.

Pei Heying H   He Linhong L   Shao Mingfeng M   Yang Zhuang Z   Ran Yan Y   Li Dan D   Zhou Yuanyuan Y   Tang Minghai M   Wang Taijin T   Gong Yanqiu Y   Chen Xiaoxin X   Yang Shengyong S   Xiang Mingli M   Chen Lijuan L  

Scientific reports 20180327 1


Janus tyrosine kinase 3 (JAK3) is expressed in lymphoid cells and is involved in the signalling of T cell functions. The development of a selective JAK3 inhibitor has been shown to have a potential benefit in the treatment of autoimmune disorders. In this article, we developed the 4-aminopiperidine-based compound RB1, which was highly selective for JAK3 inhibition, with an IC<sub>50</sub> of value of 40 nM, but did not inhibit JAK1, JAK2 or tyrosine kinase 2 (TYK2) at concentrations up to 5 µM.  ...[more]

Similar Datasets

| S-EPMC10979493 | biostudies-literature
| S-EPMC4538448 | biostudies-literature
| S-EPMC7067850 | biostudies-literature
| S-EPMC6677909 | biostudies-literature
| S-EPMC6512007 | biostudies-literature
| S-EPMC4027423 | biostudies-literature
| S-EPMC9884086 | biostudies-literature
| S-EPMC5428509 | biostudies-literature
| S-EPMC3132063 | biostudies-literature
| S-EPMC2692831 | biostudies-literature